89Bio, Inc. Stock Price, News & Analysis

89bio (NASDAQ: ETNB), a clinical-stage biopharmaceutical company specializing in liver and cardiometabolic disease therapies, has announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. The company's management will engage in a fireside chat on June 11, 2025, at 11:20 AM EDT, along with one-on-one investor meetings. The presentation will be available via webcast through 89bio's investor relations website, with replay access for approximately 30 days after the event.

89bio (Nasdaq: ETNB) has announced the approval of inducement grants for seven new employees by its Board's Compensation Committee. The grants consist of non-qualified stock options to purchase 183,885 shares of common stock, issued on May 6, 2025. These grants, made under the company's 2023 Inducement Plan, follow Nasdaq Listing Rule 5635(c)(4) and serve as employment incentives. The options' exercise price equals ETNB's closing price on the grant date and will vest over four years - 25% after one year and the remaining in 12 quarterly installments, contingent on continued employment.

89bio (NASDAQ: ETNB), a clinical-stage biopharmaceutical company specializing in liver and cardiometabolic disease therapies, has announced its management team's participation in two major healthcare investor conferences in May 2025:

1. BofA Securities 2025 Health Care Conference - Fireside chat scheduled for Wednesday, May 14, 2025, at 1:40 PM ET

2. 2025 RBC Capital Markets Global Healthcare Conference - Fireside chat scheduled for Tuesday, May 20, 2025, at 9:30 AM ET

Both presentations will be available via webcast on 89bio's investor relations website, with replays accessible for approximately 30 days after each event.

89bio (ETNB) reported Q1 2025 financial results and provided updates on its clinical programs. The company's lead drug candidate pegozafermin is advancing in multiple Phase 3 trials. The ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis trials for MASH treatment are expected to report topline data in 1H 2027 and 2028, respectively. The Phase 3 ENTRUST trial for severe hypertriglyceridemia is fully enrolled with data expected in Q1 2026. Financially, 89bio ended Q1 2025 with $638.8 million in cash and equivalents, bolstered by a $287.5 million follow-on offering. The company reported a net loss of $71.3 million for Q1 2025, compared to $51.7 million in Q1 2024, primarily due to increased R&D expenses for Phase 3 programs. R&D expenses were $64.4 million, up from $47.4 million year-over-year.

89bio (Nasdaq: ETNB), a clinical-stage biopharmaceutical company specializing in liver and cardiometabolic disease therapies, has announced its upcoming participation in the Leerink Partners Global Healthcare Conference.

The company's management will engage in a fireside chat on Monday, March 10, 2025, at 4:20 PM EST, alongside one-on-one investor meetings. Investors can access the webcast through 89bio's website investor section, with replay availability for approximately 30 days post-conference.

89bio (ETNB) reported financial results for Q4 and full year 2024, highlighting progress in its clinical trials. The company's Phase 3 ENLIGHTEN trials for MASH patients continue advancing, with topline histology data expected in 1H 2027 for non-cirrhotic patients and 2028 for cirrhotic patients. The Phase 3 ENTRUST trial in severe hypertriglyceridemia completed enrollment with 369 patients, with topline data now expected in Q1 2026.

Financial highlights include cash position of $440.0 million as of December 31, 2024, with additional gross proceeds of $287.5 million from a follow-on offering in Q1 2025. R&D expenses increased to $345.0 million for 2024, up from $122.2 million in 2023. The company reported a net loss of $367.1 million for 2024, compared to $142.2 million in 2023.

89bio (Nasdaq: ETNB) announced the approval of inducement grants by its Board's Compensation Committee. The grants consist of non-qualified stock options to purchase 163,650 shares of common stock, awarded to seven new employees on January 31, 2025. The exercise price equals the closing price of 89bio's stock on the grant date. These options will vest over four years, with 25% vesting after one year and the remaining portion vesting in 12 equal quarterly installments, contingent on continued employment. The grants were made under the company's 2023 Inducement Plan and align with Nasdaq Listing Rule 5635(c)(4).

89bio (Nasdaq: ETNB) has successfully closed its previously announced public offering, raising approximately $287.5 million in gross proceeds. The offering included 25,957,142 shares of common stock at $8.75 per share, with underwriters fully exercising their option to purchase an additional 4,285,714 shares. Additionally, the company offered pre-funded warrants for up to 6,900,000 shares at $8.749 per warrant.

The offering was managed by Goldman Sachs & Co. , Leerink Partners, and BofA Securities as lead book-running managers, with Cantor acting as book-running manager. The securities were offered through an automatically effective shelf registration statement filed with the SEC on May 23, 2023.

89bio (Nasdaq: ETNB) has announced the pricing of its upsized public offering, consisting of 21,671,428 shares of common stock at $8.75 per share and pre-funded warrants to purchase up to 6,900,000 shares at $8.749 per share. The warrants have an exercise price of $0.001 and are immediately exercisable.

The company expects to raise approximately $250.0 million in gross proceeds before deducting underwriting discounts and expenses. The underwriters have a 30-day option to purchase up to an additional 4,285,714 shares. The offering is expected to close around January 30, 2025.

Goldman Sachs & Co. , Leerink Partners, and BofA Securities are serving as lead book-running managers, with Cantor as book-running manager for the offering.